Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beck

Showing results (621-630 of 912) with videos related to

Pageof 92
Sort By:
Journal of Medicinal Chemistry|November 11, 2014
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interactionYosup Rew, Daqing Sun, Xuelei Yan, et al.
Journal of Medicinal Chemistry|April 25, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interactionYosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The IGSF1 deficiency syndrome: characteristics of male and female patientsS D Joustra, N Schoenmakers, L Persani, et al.
Journal of Medicinal Chemistry|February 20, 2014
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interactionAna Z Gonzalez, John Eksterowicz, Michael D Bartberger, et al.
Communications Earth & Environment|November 11, 2024
Intense alteration on early Mars revealed by high-aluminum rocks at Jezero craterC Royer, C C Bedford, J R Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 5, 2016
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or TachyphylaxisKjell A Svensson, Beverly A Heinz, John M Schaus, et al.
Journal of Medicinal Chemistry|April 22, 2026
Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven CancersLi Zheng, Eugene Park, Jason Lenihan, et al.
Journal of Medicinal Chemistry|January 25, 2014
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical developmentDaqing Sun, Zhihong Li, Yosup Rew, et al.
Analytica Chimica Acta|May 15, 2022
Homogeneity assessment of the SuperCam calibration targets onboard rover perseveranceJ M Madariaga, J Aramendia, G Arana, et al.
Journal of Medicinal Chemistry|September 19, 2019
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 ReceptorJunliang Hao, James P Beck, John M Schaus, et al.
Pageof 92

Showing results (621-630 of 912) with videos related to

Sort By:
Pageof 92
Journal of Medicinal Chemistry|November 11, 2014
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interactionYosup Rew, Daqing Sun, Xuelei Yan, et al.
Journal of Medicinal Chemistry|April 25, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interactionYosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The IGSF1 deficiency syndrome: characteristics of male and female patientsS D Joustra, N Schoenmakers, L Persani, et al.
Journal of Medicinal Chemistry|February 20, 2014
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interactionAna Z Gonzalez, John Eksterowicz, Michael D Bartberger, et al.
Communications Earth & Environment|November 11, 2024
Intense alteration on early Mars revealed by high-aluminum rocks at Jezero craterC Royer, C C Bedford, J R Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 5, 2016
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or TachyphylaxisKjell A Svensson, Beverly A Heinz, John M Schaus, et al.
Journal of Medicinal Chemistry|April 22, 2026
Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven CancersLi Zheng, Eugene Park, Jason Lenihan, et al.
Journal of Medicinal Chemistry|January 25, 2014
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical developmentDaqing Sun, Zhihong Li, Yosup Rew, et al.
Analytica Chimica Acta|May 15, 2022
Homogeneity assessment of the SuperCam calibration targets onboard rover perseveranceJ M Madariaga, J Aramendia, G Arana, et al.
Journal of Medicinal Chemistry|September 19, 2019
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 ReceptorJunliang Hao, James P Beck, John M Schaus, et al.
Pageof 92